Skip to main
BHC
BHC logo

BHC Stock Forecast & Price Target

BHC Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 11%
Hold 47%
Sell 11%
Strong Sell 0%

Bulls say

Bausch Health Companies Inc. reported a positive trend in revenue growth, with Salix revenues increasing by 5% year-over-year in Q3 2024, demonstrating strong organic performance and exceeding expectations. Additionally, the company's guidance for consolidated revenues was upgraded, now projected to range between $9.500 billion and $9.675 billion, reflecting confidence in operational improvements and favorable working capital dynamics. The growth in Xifaxan prescriptions, particularly for the critical 550mg formulation used in treating hepatic encephalopathy and IBS-D, further supports the bullish outlook, with a year-over-year increase of 4.6%.

Bears say

Bausch Health Companies Inc. is facing a negative financial outlook due to a projected decline in EBITDA margins from 55% in Q3 to 48.4% in Q4, along with unfavorable foreign exchange impacts expected to reduce International Rx revenues significantly. Additionally, despite some growth anticipated in the Solta Medical segment, overall International Rx revenues are forecasted to remain flat y/y at $290 million, while ongoing operational risks, including increased competition and global geopolitical tensions, pose further threats to performance. Overall, these factors contribute to a depressed market float and diminished stock multiples, suggesting challenges ahead for the company's financial stability.

BHC has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 11% recommend Buy, 47% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bausch Health Companies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bausch Health Companies Inc (BHC) Forecast

Analysts have given BHC a Buy based on their latest research and market trends.

According to 19 analysts, BHC has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bausch Health Companies Inc (BHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.